News & Updates
Showing Pharmacy articles
Showing
Real-world data affirms palbociclib–AI combo efficacy in metastatic breast cancer
The use of the combination of palbociclib plus an aromatase inhibitor (AI) in the first-line treatment setting appears to confer survival advantage on patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC), according to real-world data.
Carbapenem-sparing cephamycins effective in E coli-induced UTI
Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.